Healthcare Industry News: Medegen
News Release - August 18, 2008
Medegen Grows Product Distribution Via Co-Marketing Agreement with BardMaxPlus(R) Clear(TM) Needleless Access Device Now Available in Bard Peripherally Inserted Central Catheter (PICC) Kits
ONTARIO, Calif.--(HSMN NewsFeed)--Maximus, a business unit of leading infusion therapy firm Medegen Inc., today announced that as a result of a Co-Marketing Agreement between C.R. Bard and Medegen Inc., the MaxPlus® Clear™ needleless access connector will now be included in peripherally inserted central catheter (PICC) kits sold by Bard Access Systems. The agreement provides the extra benefits of the MaxPlus Clear product to users of Bard PowerPICC SOLO*, the newly launched PICC designed to provide the efficiency of power injection for contrast enhanced CT scans and PICC therapy combined with the simplicity of saline care and maintenance through its innovative valve technology.
The MaxPlus Clear Needleless Access Device is the first and only positive displacement connector that features complete visualization of the fluid path, which is shown to enhance patient care, leading to lower bloodstream infection and occlusion rates.
"We are pleased to join with Bard for this product initiative. PowerPICC SOLO combined with MaxPlus Clear helps medical practitioners meet the industry’s directive to put measures in place to reduce the occurrence of bloodstream infections, occlusions, and usage of heparin," said Jeff Goble, President of Medegen. “We are very excited about the synergy of these two products and the benefits this system provides to both clinicians and patients.”
The MaxPlus Clear Needleless Access Device will be packaged with all Bard PICC catheters and is also available directly from Maximus, a division of Medegen, as a sterile, pouched product.
The inclusion of MaxPlus Clear in Bard PICC kits offers customers the benefit of a needleless access device designed to assist in the reduction of common catheter complications such as bloodstream infection and catheter occlusion. These complications typically result from blood reflux in the catheter, poor flushing, and inadequate disinfection of the access port. MaxPlus Clear features Medegen’s patented positive displacement technology, which provides a bolus of fluid to clear the catheter tip upon disconnection from the device. It also features Medegen’s patented Tru-Swab® top which acts as a double-sealed barrier to contamination and allows for true disinfection during pre-access swabbing and a clear housing minimizing the occurrence of poor flushing.
Medegen’s MaxPlus Clear provides features not previously available to clinicians, and is new technology for the industry.
MaxPlus Clear answers the need of medical practitioners in a number of ways:
1. Provides for complete visualization of the fluid path during priming and flushing of the device
2. Promotes an “occlusion- and contaminate-free” line
3. Promotes compliance with best practices and aseptic technique
4. Promotes the use of saline flush and lock vs. heparin
5. Promotes complete flushing
This in turn helps reduce bloodstream infections, occlusions, heparin usage, false positive blood cultures, nursing time, and all the costs associated with these.
About Medegen Inc.
Medegen is a leading innovator in infusion therapy, focused on helping hospitals drive greater clinical performance for improved patient care. The growing company provides clinically superior medical products and reliable, cost-effective manufacturing services to the medical community through its three operating units: Manufacturing Services, Maximus and KippMed. Manufacturing Services provides cost-effective contract manufacturing solutions to medical device, drug delivery and pharmaceutical companies. KippMed manufactures and markets IV therapy components for the OEM market, drawing from a 25-year history in IV component supply. Maximus develops, manufactures and markets needleless intravenous therapy products for the acute care market. The Maximus line of medical products features patent-protected technologies which improve patient outcomes and greatly reduce bloodstream infection rates. Medegen is headquartered in Ontario, Calif. with executive offices in Scottsdale, Ariz. and operations in Tijuana, Mexico. For more visit http://www.Medegen.com/.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.